Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.

Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

Curr Med Res Opin. 2012 Jul;28(7):1155-62. doi: 10.1185/03007995.2012.705264. Epub 2012 Jun 28.

PMID:
22738777
2.

Implementing a standardized pharmacist assessment and evaluating the role of a pharmacist in a multidisciplinary supportive oncology clinic.

Mancini R.

J Support Oncol. 2012 May-Jun;10(3):99-106. doi: 10.1016/j.suponc.2011.09.005. Epub 2012 Jan 23.

PMID:
22266155
3.

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.

Gebbia V, Bellavia G, Ferraù F, Valerio MR.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S49-59. doi: 10.1517/14740338.2011.645803. Epub 2011 Dec 13. Review.

PMID:
22149481
4.

Reminder packaging for improving adherence to self-administered long-term medications.

Mahtani KR, Heneghan CJ, Glasziou PP, Perera R.

Cochrane Database Syst Rev. 2011 Sep 7;(9):CD005025. doi: 10.1002/14651858.CD005025.pub3. Review.

PMID:
21901694
5.

A pharmacoepidemiologic analysis of the impact of calendar packaging on adherence to self-administered medications for long-term use.

Zedler BK, Joyce A, Murrelle L, Kakad P, Harpe SE.

Clin Ther. 2011 May;33(5):581-97. doi: 10.1016/j.clinthera.2011.04.020.

PMID:
21665043
6.

Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.

Foulon V, Schöffski P, Wolter P.

Acta Clin Belg. 2011 Mar-Apr;66(2):85-96. Review.

PMID:
21630604
7.

Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel.

Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, Patel RA, Schwartz R, Tamés MJ, Terkola R, Vadnais B, Wright D, Meier K.

J Oncol Pract. 2011 Jan;7(1):7-12.

8.

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.

Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M.

Patient Prefer Adherence. 2011 Jan 20;5:73-84. doi: 10.2147/PPA.S15702.

9.

Does packaging with a calendar feature improve adherence to self-administered medication for long-term use? A systematic review.

Zedler BK, Kakad P, Colilla S, Murrelle L, Shah NR.

Clin Ther. 2011 Jan;33(1):62-73. doi: 10.1016/j.clinthera.2011.02.003. Review.

PMID:
21397775
10.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS.

J Clin Oncol. 2010 May 10;28(14):2381-8. doi: 10.1200/JCO.2009.26.3087. Epub 2010 Apr 12.

11.

Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature.

Schwappach DL, Wernli M.

Eur J Cancer Care (Engl). 2010 May;19(3):285-92. doi: 10.1111/j.1365-2354.2009.01127.x. Epub 2009 Aug 25. Review.

PMID:
19708929
12.

Medication adherence: its importance in cardiovascular outcomes.

Ho PM, Bryson CL, Rumsfeld JS.

Circulation. 2009 Jun 16;119(23):3028-35. doi: 10.1161/CIRCULATIONAHA.108.768986. Review.

13.

Medication compliance and persistence: terminology and definitions.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK.

Value Health. 2008 Jan-Feb;11(1):44-7. doi: 10.1111/j.1524-4733.2007.00213.x. Review.

14.

The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.

Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM.

Int J Clin Pract. 2008 Jan;62(1):76-87. Epub 2007 Nov 5. Review.

15.

Safe practices and financial considerations in using oral chemotherapeutic agents.

Bartel SB.

Am J Health Syst Pharm. 2007 May 1;64(9 Suppl 5):S8-S14. Review.

PMID:
17468158
16.

A checklist for medication compliance and persistence studies using retrospective databases.

Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M.

Value Health. 2007 Jan-Feb;10(1):3-12.

17.
18.

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, Beham A, Figer A, Dufour P, Patel KK, Cowell W, Garrison LP.

Br J Cancer. 2006 Apr 24;94(8):1122-9.

Items per page

Supplemental Content

Write to the Help Desk